Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Outcome of Using Intravenous Immunoglobulin (Ivig) in Critically Ill Covid-19 Patients’: A Retrospective, Multi-Centric Cohort Study Publisher Pubmed



Salehi M1 ; Barkhori Mehni M2 ; Akbarian M2 ; Fattah Ghazi S3 ; Khajavi Rad N4 ; Moradi Moghaddam O5 ; Jamali Moghaddam SR6 ; Hosseinzadeh Emam M7 ; Abtahi SH8 ; Moradi M9 ; Ghiasvand F1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Keshavarz Boulevard, Tehran, Iran
  2. 2. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Anesthesiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Internal Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Trauma and Injury Research Center, Critical Care Medicine Department, Iran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Infectious Disease, School of Medicine, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Anesthesiology, Critical Care Medicine Subspecialty Fellowship, Iran University Medical Sciences, Tehran, Iran
  8. 8. Department of Internal Medicine, School of Medicine, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
  9. 9. School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Source: European Journal of Medical Research Published:2022


Abstract

Background: During the COVID-19 pandemic, different treatments have been used in critically ill patients. Using intravenous immunoglobulin (IVIG) has been suggested in various studies as an effective option. Our study aims to access the efficacy of IVIG in critically ill COVID-19 patients. Methods: In this retrospective matched cohort study, records of three tertiary centers with a large number of COVID-19 admissions were evaluated and used. Based on treatment options, patients were divided into two groups, standard COVID-19 treatment (109 patients) and IVIG treatment (74 patients) patients. Also, the effect of IVIG in different dosages was evaluated. Patients with IVIG treatment were divided into three groups of low (0.25 gr/kg), medium (0.5 gr/kg), and high (1 gr/kg) dose. Data analysis was performed using an independent t test and one-way analysis of variance (ANOVA) to compare the outcomes between two groups, including duration of hospitalization, intensive care unit (ICU) length of stay, and mortality rate. Results: The duration of hospitalization in the IVIG group was significantly longer than standard treatment (13.74 days vs. 11.10 days, p < 0.05). There was no significant difference between the two groups in ICU length of stay, the number of intubated patients, and duration of mechanical ventilation (p > 0.05). Also, initial outcomes in IVIG subgroups were compared separately with the standard treatment group. The results indicated that only the duration of hospitalization in the IVIG subgroup with medium dose is significantly longer than the standard treatment group (p < 0.01). Conclusion: Our data indicate that the use of IVIG in critically ill COVID-19 patients could not be beneficial, based on no remarkable differences in duration of hospitalization, ICU length of stay, duration of mechanical ventilation, and even mortality rate. © 2022, The Author(s).
Related Docs
1. Potential Therapeutic Approach of Intravenous Immunoglobulin Against Covid-19, Allergy# Asthma and Clinical Immunology (2021)
2. Efficacy of Intravenous Immunoglobulins (Ivig) in Covid-19 Patients: A Systematic Review and Meta-Analysis, Research in Pharmaceutical Sciences (2023)
3. Immune-Based Therapeutic Approaches in Covid-19, Biomedicine and Pharmacotherapy (2022)
4. Recent Advances in Antibody-Based Immunotherapy Strategies for Covid-19, Journal of Cellular Biochemistry (2021)
5. Recent Advances in Passive Immunotherapies for Covid-19: The Evidence-Based Approaches and Clinical Trials, International Immunopharmacology (2022)
6. An Overview on the Treatments and Prevention Against Covid-19, Virology Journal (2023)
7. Immunomodulatory-Based Therapy As a Potential Promising Treatment Strategy Against Severe Covid-19 Patients: A Systematic Review, International Immunopharmacology (2020)
8. Immunology, Immunopathogenesis and Immunotherapeutics of Covid-19; an Overview, International Immunopharmacology (2021)
Experts (# of related papers)
Nima Rezaei (3)
Farshid Noorbakhsh (1)